The FDA recently announced that is has issued warning letters to 17 website operators for illegally selling opioids that are unapproved or misbranded, meaning they were sold without a prescription ...

The US Food and Drug Administration has issued 7 warning letters to companies illegally marketing products containing 7-hydroxymitragynine (7-OH), which is found in trace amounts in kratom.

The U.S. Food and Drug Administration has issued warning letters to 17 website operators for illegally selling unapproved and misbranded opioids online in violation of the Federal Food, Drug, and ...

The U.S. Food and Drug Administration sent letters to seven companies that sell opioid alternative products containing ...

“There are no FDA-approved drugs containing 7-OH, and it is illegal to market any drugs containing 7-OH,” the FDA said.

The FDA has issued warnings to seven companies for illegally marketing kratom-based products containing 7-OH, a compound not approved for food or supplements, citing safety concerns and unproven ...

FDA issues warning to AcelRx for making false and misleading claims about the risks and benefits of Dsuvia. [ press release ]. Silver Springs, MD: US Food and Drug Administration; February 16, 2021.

Some medical researchers say 7-OH products made from kratom extracts could have the potential to create addiction problems, ...

The U.S. Food and Drug Administration is bringing attention to an unlawful dietary supplement that is turning up in online purchases and retail outlets.

A print advertisement of Alkermes Plc's addiction treatment, Vivitrol, is false or misleading as it omits important risk information associated with its use, the Food and Drug Administration said ...

“A Perfect Storm”: OPDP Sends Warning Letter Regarding Print Advertisement for Drug to Treat Opioid Use Disorder—Failure to Disclose Serious Risks, Including Potential for Fatal Overdose ...

The U.S. Food and Drug Administration on Tuesday sent warning letters to nine online networks operating a total of 53 websites to stop illegally marketing unapproved versions of opioid medications.